The biomarker is just to prove that a patient actually has AD.
It isn't used to measure efficacy.
The only efficacy measures are the cognition tests.
=====
Yes, because half the XanADu sample didn't have AD, statistical significance is hard to achieve on the small number of real AD cases.
The biomarker is just to prove that a patient actually has AD.It...
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $76.57M | |||
| Open | High | Low | Value | Volume |
| 2.6¢ | 2.6¢ | 2.6¢ | $43.49K | 1.672M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 3018189 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 6345033 | 13 |
View Market Depth
| Last trade - 10.12am 02/10/2024 (20 minute delay) ? |
| ACW (ASX) Chart |